SSG
JANX icon

Summit Securities Group’s Janux Therapeutics JANX Stock Holding History

Summit Securities Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.48K Buy
+487
New +$7.05K ﹤0.01% 895
2024
Q4 		– Sell
-700
Closed -$32K – 770
2024
Q3 		$32K Hold
700
– – 0.01% 275
2024
Q2 		$29K Buy
+700
New +$32.9K 0.01% 346

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Summit Securities Group's JANX Position: Q2 2026 in Review

Summit Securities Group opened a new position in Janux Therapeutics (JANX) in Q2 2026: 487 shares worth $7.48K. The stake represents ﹤0.01% of the portfolio and ranks #895 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in JANX as recently as Q3 2024.

Summit Securities Group first reported a position in JANX in Q2 2024 and has held it in 3 quarters since. The position peaked at $32K in Q3 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Summit Securities Group held 487 shares of Janux Therapeutics worth $7.48K as of Q2 2026.
  • Janux Therapeutics was a new Summit Securities Group position in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #895 holding.
  • Summit Securities Group first reported a position in Janux Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Summit Securities Group's Janux Therapeutics position peaked at $32K in Q3 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.